A CK7-positive result on a pathology report means that cells in your tissue sample contain cytokeratin 7, a structural protein normally found in the lining cells of certain organs, including the lungs, breast, thyroid, and urinary tract. On its own, CK7 positivity does not diagnose any specific disease. Instead, it is one piece of a larger puzzle that pathologists use to figure out where a tumor originated or to narrow down a diagnosis when the answer is not obvious from the tissue alone. The result becomes meaningful only when paired with other markers and clinical context.
What Cytokeratin 7 Actually Is
Your cells have an internal scaffolding system made of tiny protein filaments. One family of these filaments, called intermediate filaments, provides mechanical strength to cells and tissues and plays a role in cell survival and movement.1PubMed. Intermediate filament: structure, function, and applications in cytology Cytokeratins are a specific type of intermediate filament found in epithelial cells, meaning the cells that line the surfaces and cavities of your organs. There are about 20 different cytokeratins, and different tissues express different combinations of them. CK7 is one member of this family, and it shows up in a very specific set of tissues.
In healthy tissue, CK7 is found in the lining cells of the lungs, breast, bile ducts, the collecting ducts of the kidney, the cervix, and the mesothelium (the thin membrane covering internal organs). It also strongly stains the transitional epithelium of the urinary bladder. Critically, CK7 is normally absent from the gastrointestinal tract, from liver cells, and from the skin.2Experimental Cell Research. Tissue distribution of keratin 7 as monitored by a monoclonal antibody This pattern of “present here, absent there” is exactly what makes CK7 useful in cancer diagnostics. If a tumor stains positive for CK7, it likely originated from one of those CK7-expressing tissues rather than from, say, the colon or the skin.
Why Pathologists Pair CK7 With CK20
CK7 alone narrows the possibilities, but it is most powerful when combined with another cytokeratin called CK20. CK20 has an almost complementary distribution in the body: it is abundant in the gastrointestinal tract and the bladder lining but absent from many of the organs where CK7 is found. By testing a tumor for both markers, pathologists create a two-by-two grid with four possible profiles, and each profile points toward different organ origins.
A large tissue microarray study covering more than 15,000 cancer samples from 120 tumor types found that the CK7/CK20 combination was most diagnostically useful when CK20 was positive. In that scenario, CK7 negativity strongly suggested a colorectal origin, while CK7 positivity argued for a bladder (urothelial) origin or mucinous ovarian cancer.3PubMed. Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers In a separate study of metastatic carcinomas, all cases from the lung, breast, and thyroid followed a CK7-positive, CK20-negative pattern, while about 90% of colon cancers followed the opposite pattern.4Indian Journal of Pathology and Oncology. Utility of immunohistochemistry with CK7 and CK20 in metastatic carcinoma
The four profiles break down roughly like this:
- CK7+/CK20−: The most common pattern, seen in cancers of the lung, breast, thyroid, endometrium, and ovary (non-mucinous types).
- CK7−/CK20+: Strongly associated with colorectal cancer.
- CK7+/CK20+: Seen in cancers of the pancreas, bile ducts (cholangiocarcinoma), bladder, stomach, and some mucinous ovarian tumors.
- CK7−/CK20−: Points toward organs like the prostate, kidney, liver, or certain squamous cell cancers.
These patterns are guidelines, not certainties. A pathology review found that the CK7/CK20 combination sometimes made a major contribution to the final diagnosis, sometimes made a minor one (confirming what other markers had already shown), and sometimes contributed nothing because the staining pattern did not match the expected profile for the final diagnosis.5PubMed Central. Revisiting the use of CK7 and CK20 immunohistochemical stains in pathological diagnoses In other words, CK7/CK20 is a starting framework, and pathologists always layer on additional markers to refine the answer.
When Both CK7 and CK20 Are Positive
A result showing positivity for both markers simultaneously is less common than the CK7+/CK20− pattern, but it comes up regularly with tumors from the gastrointestinal and genitourinary tracts. In a survey of 435 cases, roughly 62% of pancreatic cancers and 43% of bile duct cancers showed this dual-positive profile. About a quarter of bladder transitional cell carcinomas and a smaller fraction of gastric cancers also fell into this group.6Modern Pathology. Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases The overlap means a dual-positive result still requires further testing to distinguish among these possibilities. Pathologists reach for organ-specific markers like CDX-2 (for intestinal origin) or PAX-8 (for kidney, thyroid, or gynecologic origin) to break the tie.
Even some rarer tumors can show this dual positivity. Intestinal-type sinonasal adenocarcinoma, a rare cancer of the nasal cavity, was found to be CK20-positive across all tested cases, with the majority also expressing CK7.7Journal of Clinical Pathology. Expression pattern of CK7, CK20, CDX-2, and villin in intestinal-type sinonasal adenocarcinoma Cases like these illustrate why pathologists treat the CK7/CK20 profile as a rough compass rather than a GPS coordinate.
Tracking Down a Cancer of Unknown Primary
One of the most important uses for CK7 testing is in what pathologists call a carcinoma of unknown primary, or CUP. This is the scenario where a metastatic tumor shows up somewhere in the body but imaging and clinical workup have not identified where it started. The CK7/CK20 combination is among the first tests run to help narrow down the organ of origin, because it can quickly sort tumors into broad categories.
The CK7/CK20 pair is particularly helpful in certain differential diagnoses. Distinguishing a lung adenocarcinoma from a colorectal adenocarcinoma that has spread to the lungs, or telling apart a primary ovarian tumor from colon cancer that has metastasized to the ovary, are two settings where this stain combination has proven most useful.8European Journal of Cancer Prevention. Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer
But the system has blind spots. A published case report described a pelvic mass that stained CK7-positive and CK20-negative. Based on that profile, the suspected origins included lung, breast, thyroid, or pancreas. Imaging did not find tumors at any of those sites. The mass turned out to be a prostate adenocarcinoma, a tumor type that is typically CK7-negative and CK20-negative.9Cancer Research and Treatment. Cancer of Unknown Primary Finally Revealed to Be a Metastatic Prostate Cancer: A Case Report No immunohistochemical test is perfectly specific, and exceptions like this are a reminder that CK7 results must be interpreted alongside clinical findings and additional stains.
Telling Look-Alike Cancers Apart
Several organ systems have cancers that look strikingly similar under the microscope, and CK7 plays a key role in sorting them out. Ovarian cancer is a good example. Nearly all primary ovarian carcinomas, including the mucinous subtype, show strong CK7 expression. This makes CK7 useful for distinguishing a primary ovarian tumor from colon cancer that has metastasized to the ovary, because colorectal tumors are typically CK7-negative. A study using tissue microarrays concluded that the combination of CK7 and CDX-2 (an intestinal marker) was the best pairing for making this distinction.10Journal of Korean Medical Science. The Usefulness of CDX-2 for Differentiating Primary and Metastatic Ovarian Carcinoma: An Immunohistochemical Study Using a Tissue Microarray
Lung and thyroid tumors pose a different challenge. Both can express CK7 and a marker called TTF-1, which means that when a patient has tumors in both locations, it is not immediately clear whether one metastasized from the other or whether the patient has two separate primary cancers. A case report described a patient with simultaneous lung and thyroid adenocarcinomas; both were CK7-positive and TTF-1-positive. Only by testing for thyroglobulin (positive in the thyroid tumor, negative in the lung tumor) could pathologists confirm they were two independent cancers.11PubMed Central. Concomitant pulmonary and thyroid tumors identified by FDG PET/CT and immunohistochemical techniques The overlap of CK7 and TTF-1 between lung and thyroid cancers is well documented, and additional markers are needed whenever both organs are involved.12PubMed. Napsin A Expression in Subtypes of Thyroid Tumors: Comparison with Lung Adenocarcinomas
CK7 as a Prognostic Signal in Colorectal Cancer
Because CK7 is normally absent from colon and rectal tissue, finding CK7 positivity in a colorectal tumor is unusual and raises different questions. Rather than helping identify where the tumor came from (its origin is already known), CK7 staining in these tumors may carry prognostic information. In a study of colorectal carcinomas, patients whose tumors had CK7 positivity in more than 10% of cells had a significantly shorter cancer-specific survival compared with CK7-negative patients, with a mean survival of about 5 years versus roughly 7.7 years.13PubMed Central. Cytokeratin 7 expression as a predictor of an unfavorable prognosis in colorectal carcinoma The effect was also present at a lower threshold of 1% positivity, suggesting that even modest CK7 expression in these tumors might flag a more aggressive biology.
Another study looking at patients with low rectal cancer after neoadjuvant therapy (chemotherapy and radiation given before surgery) found that CK7-positive patients had a higher proportion of poor treatment response compared with CK7-negative patients.14PubMed Central. Cytokeratin 7 Expression and Mismatch Repair Status for Survival Prediction in Patients With Low Rectal Cancer After Neoadjuvant Therapy If confirmed in larger studies, CK7 testing in colorectal tumors could eventually help guide how aggressively a patient is treated, though this is not yet part of routine clinical guidelines.
CK7 Positivity Outside of Cancer
Not every CK7-positive result comes from a cancer specimen. CK7 staining also appears in non-cancerous conditions, and understanding this can prevent unnecessary alarm. In the liver, for example, healthy liver cells (hepatocytes) do not normally express CK7. But in various liver diseases, hepatocytes in certain zones of the liver lobule can start producing the protein. A study of non-neoplastic liver tissue found that CK7-positive hepatocytes in the center of liver lobules were associated with older age, elevated liver enzymes, and scarring around the central veins. This CK7 expression appeared to be a non-specific finding, not tied to any one underlying liver disease, and may represent the liver’s regenerative response or activation of progenitor cells.15PubMed. Aberrant cytokeratin 7 expression of centrilobular hepatocytes: a clinicopathological study
In the cervix, CK7 has been studied as a marker for the progression of low-grade precancerous changes. In cervical intraepithelial neoplasia (CIN), the proportion of lesions expressing CK7 rises with the grade of the abnormality. About a third of CIN1 lesions (the mildest grade) were CK7-positive, compared with 45% of CIN2 and 60% of CIN3 (the most severe).16The American Journal of Surgical Pathology. Predictive Value of Cytokeratin 7 Immunohistochemistry in Cervical Low-grade Squamous Intraepithelial Lesion as a Marker for Risk of Progression to a High-grade Lesion This suggests CK7 staining in a cervical biopsy with a low-grade lesion could help predict which lesions are more likely to progress, though it would be used alongside other clinical factors rather than as a standalone decision tool.
When CK7 Results Mislead
There are several situations where CK7 staining can send pathologists down the wrong path if they rely on it too heavily. Tumors do not always follow the expected staining rules. A prostate cancer that unexpectedly stains CK7-positive, as in the case report discussed earlier, is one example. More broadly, poorly differentiated tumors (those that have lost many of the features of their tissue of origin) can gain or lose cytokeratin expression in unpredictable ways.
Certain non-epithelial tumors also pose a trap. Epithelioid angiosarcoma, a rare and aggressive vascular tumor, can show strong positivity for cytokeratins, including some that overlap with epithelial markers. In a reported case of tonsillar epithelioid angiosarcoma, the tumor expressed several cytokeratins and could easily have been confused with a poorly differentiated squamous cell carcinoma. CK7 was negative in that particular case, but the broader point stands: cytokeratin positivity does not automatically mean a tumor is a carcinoma. Pathologists must use vascular markers like CD31 or ERG to distinguish such cases.
Technical factors can also introduce error. How a tissue sample is processed, the specific antibody clone used for CK7 staining, and the threshold chosen for calling a result “positive” versus “negative” all affect the outcome. The study on colorectal cancer prognosis used both a 1% and a 10% positivity cutoff and found different results at each threshold. There is no universally agreed-upon cutoff for CK7 positivity across all tumor types, which means pathologists exercise judgment when reading these stains. If you are reviewing your own pathology report, the written interpretation by the pathologist matters more than the raw staining result.
What CK7 Does Not Tell You
A CK7-positive result, on its own, says nothing about whether a tumor is benign or malignant. CK7 is a normal protein found in healthy tissues, and its presence in a biopsy simply tells the pathologist something about the type of cell present. The finding is about origin and cell type, not about aggressiveness or treatment. It is also not a cancer screening test. CK7 immunohistochemistry is ordered after a suspicious mass or lesion has already been biopsied and a pathologist needs additional information to classify it.
CK7 does not directly inform treatment decisions in most cancers. Targeted therapies and immunotherapies are chosen based on other molecular markers, such as specific gene mutations, microsatellite instability status, or PD-L1 expression. CK7’s contribution is upstream of those decisions: it helps ensure the tumor is correctly classified so that the right treatment guidelines apply. If a metastatic tumor in the liver is mistakenly classified as a primary liver cancer instead of a metastasis from the lung, the patient could receive the wrong treatment regimen. That is the kind of error CK7 testing helps prevent.
Reading Your Pathology Report
If you see “CK7 positive” on your pathology report, it will almost always be listed in a section called immunohistochemistry or “IHC panel,” alongside results for several other markers. The pathologist uses the full pattern of positive and negative stains together with the microscopic appearance of the cells to reach a final diagnosis, which is stated separately in the report, usually at the top or in a “diagnosis” line.
You may also see descriptions like “diffuse strong CK7 positivity” or “focal weak CK7 positivity.” Diffuse and strong means the protein was abundant across most of the tumor cells, which is more typical of tissues that normally express CK7. Focal and weak means only scattered cells stained, which could indicate aberrant expression or a tumor with mixed features. In colorectal cancer, even focal expression may carry prognostic meaning, as noted earlier. In other tumor types, the intensity and extent of staining help the pathologist weigh how much diagnostic significance to assign the result.
If the report lists CK7 alongside CK20, TTF-1, CDX-2, PAX-8, or other abbreviations, each of these is a different immunohistochemical stain targeting a different protein. Together they form a profile, and the pathologist interprets that profile as a whole. Asking your doctor to walk you through the IHC panel can be more informative than searching for the meaning of any single marker in isolation. The diagnosis at the top of the report already reflects the pathologist’s expert interpretation of all these stains in context, and that diagnosis is what drives your clinical care.